BioFire Defense, LLC appears in FDA device records as the applicant behind a control kit for a molecular diagnostic panel, and its own published material describes a broader role as a contract research, development, and manufacturing organization serving U.S. government and bioMérieux needs. The company's public product pages list instruments and panels spanning real-time PCR, DNA amplification and Hi-Res Melting. The filings and company pages below describe documented products, submission dates and stated organizational relationships; they do not establish sales volumes, clinical performance or total portfolio size. [1][5][7]

The Warrior Panel control kit submission

FDA records show K262842, the BioFire Warrior Panel Control Kit, filed by BioFire Defense, LLC under product code PMN and regulation number 866.3920, with a decision date of November 4, 2026 and a decision description of Substantially Equivalent. The submission was received August 12, 2026, classified as Traditional, reviewed by the Microbiology advisory committee, and accompanied by a summary. The device name in the openFDA fields reads as assayed external control material for microbiology nucleic acid amplification assays. [1]

A separate FDA record lists K243822 under the device name BioFire Warrior Panel and BioFire Warrior Panel Control Kit, with BioFire Defense, LLC as applicant. A third-party summary of K262842 describes the test system as the BIOFIRE FILMARRAY 2.0 or BIOFIRE FILMARRAY TORCH Systems and the composition as dried synthetic DNA segments. [2][8]

Documented instruments and panels

BioFire Defense's products page states that the company develops, manufactures and sells instruments for real-time detection of pathogens and emerging infectious diseases, naming DNA amplification, real-time PCR and Hi-Res Melting as the underlying technology. The listed product line includes the BioFire FilmArray, SPOTFIRE and TORCH systems, the portable RAZOR Mk II instruments, and panels and test kits. [7]

A company information sheet describes the BioFire Global Fever Panel as detecting six targets in one test from EDTA whole blood at moderate CLIA complexity, covering Leptospira, chikungunya, dengue, Plasmodium species and Plasmodium falciparum, with a BIOFIRE SHIELD Control Kit available for that panel. The same sheet describes Department of Defense controlled panels covering Bacillus anthracis, Coxiella burnetii, Francisella tularensis, Yersinia pestis, Ebolavirus and Marburg marburgvirus, manufactured solely for use by U.S. Department of Defense laboratories and laboratories the Department designates. [3]

Stated organizational relationships

BioFire Defense's About page describes the company as a wholly owned affiliate of bioMérieux and an independent contract research, development, and manufacturing organization with commercial infrastructure for the U.S. Government and bioMérieux, governed by an independent board of directors. Those ownership and governance statements come from the company's own page; the FDA filing identifies the applicant as BioFire Defense, LLC without addressing parentage. [5]

The About page also states that the company aligns readiness across U.S. defense, government and public health agencies to protect against biothreats and emerging infectious diseases, and invites organizations to contact its experts about syndromic testing. The products page states that the company's technology is the standard for the US Military and US Agencies, a characterization published by BioFire Defense rather than an independent assessment. [5][7]

What the filing record shows and does not show

The supplied portfolio snapshot, retrieved November 20, 2026, contains one linked 510(k) record with a single Substantially Equivalent decision, and the record sample contains that same K262842 entry. These counts describe the supplied filings at that retrieval time, not total company sales, total portfolio or safety performance. An FDA establishment registration search for owner operator number 8020790 returns 15 results, a listing count that does not by itself establish which devices are currently marketed. [1][6]

The filing address for K262842 is 79 W 4500 S, Suite 14, Salt Lake City, UT 84107, with David Rabiger listed as contact. That address is a correspondence detail in the submission and is not treated here as a verified headquarters. Details such as manufacturing sites, customers, certifications, pricing and commercial availability are not established by the numbered sources. [1][2]